What this study is
The goal of the ADHERE-HF study is to evaluate whether care-embedded, operationally delivered digital outreach improves medication refill, adherence, and clinical outcomes among adults with heart failure who are overdue for a refill of an eligible guideline-directed medical therapy (GDMT) medication.
The main question it aims to answer is: Does digital outreach using interactive text messages or automated telephone calls increase short-term refill of overdue heart failure medications compared with usual care?
The study will evaluate the effectiveness of a digital outreach strategy delivered through existing health system communication channels. Members who have opted in to pharmacy text messaging will receive interactive text messages, while those who have not opted in will receive an interactive automated telephone call. The comparison group will receive usual care with no additional outreach.
What's being tested
- Digital Outreach
Intervention · BEHAVIORAL
Participants assigned to this arm will receive digital outreach encouraging refill of overdue guideline-directed medical therapy (GDMT) medications for heart failure. Participants who have opted in to pharmacy text messaging at the time of outreach will receive interactive text messages. Participants who have not opted in to pharmacy text messaging will receive an interactive automated telephone call. Participants may receive additional outreach during the 12-month intervention period if another eligible GDMT medication becomes overdue.
Study details
- Official title
- Adherence Through Digital Health: Evaluating Randomized Engagement in Heart Failure
- Sponsor
- Kaiser Permanente
- Conditions
- CHF - Congestive Heart Failure
- Enrolling
- 13,714 people
- Starts
- 2026-09-21
- Est. completion
- 2028-03
- Design
- Open-label, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Age ≥18 years
- Active KPNC membership
- Heart failure diagnosis documented at least 6 months before the index date, with a documented EF
- Prescribed at least one eligible GDMT medication for ≥6 months:; HFpEF (EF≥50%): ARNI (sacubitril/valsartan); MRA; SGLT2i; HFrEF or HFmrEF (EF <50%): ARNI (sacubitril/valsartan), ACEi, or ARB; Beta-blocker (bisoprolol, carvedilol, or sustained-release metoprolol succinate); MRA; SGLT2i
- At least one unfilled refill for an eligible GDMT medication that is 7-13 days overdue at index
You can't join if
- Documented allergy or intolerance to all eligible GDMT medications for which the patient is overdue
- Receiving hospice or comfort-focused care
- Skilled nursing facility stay within prior 12 months
- No valid telephone number on file through which the patient could be reached by text message or automated telephone call
- Opted out of receiving pharmacy medication adherence outreach from Kaiser Permanente
- Other conditions that prevent outreach
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openKaiser Permanente Division of Research
Pleasanton, California, United States
Study team
Sponsor
Kaiser Permanente
Study ID ADHERE-HF
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.